NSCLC metastatic/molecular target

 
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 02/01/2020)

EGFR
ZENITH20 Poziotinib (Spectrum)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.

ALK
Currently no trials

KRAS
Currently no trials

RET
Currently no trials

BRAF
Currently no trials

C-MET
CINC280 (Novartis) -> for 1st line
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer.
(only cohort 7 open)

ROS1
BFAST (Roche)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).
(only cohort D open)

HER2
ZENITH20 Poziotinib (Spectrum)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.